Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech

Published 11/04/2022, 16:52
Updated 11/04/2022, 17:43
© Reuters.  Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech
MTNB
-

BioNTech SE (NASDAQ: BNTX) and Matinas BioPharma Holdings Inc (NYSE: MTNB) have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas' proprietary LNC platform technology.

  • The companies will collaborate on formulation, optimization, and in vitro testing.
  • "We are thrilled to partner with this world-class organization to demonstrate the capabilities of our LNC platform further and potentially provide an opportunity for the oral administration of vaccines or other treatments,' said Jerome Jabbour, CEO & Co-Founder of Matinas.
  • Related: Matinas BioPharma Stock Jumps After Meningitis Candidate Data.
  • Under the agreement terms, Matinas will receive an upfront access fee to work exclusively with BioNTech and additional research funding from BioNTech. Specific deal terms were not disclosed.
  • The parties have also commenced discussions on a license agreement for Matinas' LNC platform technology.
  • Price Action: MTNB shares are up 2.97% at $0.80, and BNTX shares are down 0.70% at $169.06 on Monday's last check.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.